Media Center

Investor Relations

Overview
Newsroom
Events
Stock Information
Financials
- SEC Filings
- Annual Reports
Governance
- Governance Documents
- Committee Composition
Investor Resources
Investor Email Alerts

Investor contact

760-603-2331

Media contact

760-603-4679

Press Releases

Year

Nov 07, 2024

Ionis to present at upcoming investor conferences

Nov 06, 2024

Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome

Nov 06, 2024

Ionis reports third quarter 2024 financial results

Nov 04, 2024

Ionis announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAE

Oct 23, 2024

Ionis to hold third quarter 2024 financial results webcast

Oct 21, 2024

WAINZUA (eplontersen) recommended for approval in the EU by CHMP for the treatment of adults with polyneuropathy associated with hereditary transthyretin-mediated amyloidosis

Oct 03, 2024

New positive donidalorsen data to be presented at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

Oct 01, 2024

Zilganersen granted U.S. FDA Fast Track designation for people living with Alexander disease

Sep 09, 2024

Ionis announces pricing of $500.3 million public offering

Sep 09, 2024

Ionis announces proposed public offering of common stock

Aug 28, 2024

Ionis to present at upcoming investor conferences

Aug 01, 2024

Ionis reports second quarter 2024 financial results

Jul 22, 2024

Ionis announces positive detailed results from the HALOS Study of ION582 in people with Angelman syndrome

Jul 19, 2024

Ionis to hold second quarter 2024 financial results webcast

Jul 18, 2024

Ionis completes enrollment in pivotal trial evaluating zilganersen in people living with Alexander disease

Jul 08, 2024

Ionis announces webcast to report HALOS study results for ION582 in Angelman syndrome

Jun 25, 2024

Ionis announces olezarsen FCS New Drug Application accepted for Priority Review and enrollment in Phase 3 sHTG program completed

Jun 18, 2024

Ionis announces expanded licensing agreement with Otsuka in Asia Pacific for investigational medicine donidalorsen in hereditary angioedema

Jun 17, 2024

Ionis to present at TD Cowen Genetic Medicines & RNA Summit

May 31, 2024

Ionis presents positive results from OASIS-HAE and OASISplus studies of investigational medicine donidalorsen in patients with hereditary angioedema

May 28, 2024

Ionis to hold donidalorsen Phase 3 data webcast

May 23, 2024

New data from the Phase 3 NEURO-TTRansform study evaluating WAINUA™ (eplontersen) to be presented at the 2024 International Symposium on Amyloidosis (ISA)

May 16, 2024

Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis

May 16, 2024

Ionis announces positive topline results from Phase 1/2a trial of ION582 for Angelman syndrome

May 15, 2024

Ionis to host 2024 virtual Annual Meeting of Stockholders

May 07, 2024

Ionis reports first quarter 2024 financial results

Apr 25, 2024

Ionis Publishes 2023 Corporate Responsibility Report

Apr 23, 2024

Ionis to hold first quarter 2024 financial results webcast

Apr 07, 2024

Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome

Apr 01, 2024

Ionis to present at upcoming investor conferences

Mar 28, 2024

Ionis to hold olezarsen Phase 3 data webcast

Mar 25, 2024

Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology (ACC) annual meeting

Mar 13, 2024

Ionis announces positive results from Phase 2 study of ION224, an investigational medicine demonstrating clinical efficacy in the treatment of NASH/MASH

Feb 29, 2024

Ionis announces new chief global product strategy officer to lead next phase of commercial growth

Feb 28, 2024

Ionis to present at upcoming investor conferences

Feb 21, 2024

Ionis reports fourth quarter and full year 2023 financial results

Feb 15, 2024

Olezarsen receives Orphan Drug designation from U.S. FDA for familial chylomicronemia syndrome

Feb 08, 2024

Eplontersen granted U.S. FDA Fast Track designation for patients with transthyretin-mediated amyloid cardiomyopathy

Feb 07, 2024

Ionis to hold fourth quarter and full year 2023 financial results webcast

Jan 22, 2024

Ionis announces positive topline results from Phase 3 OASIS-HAE study of investigational donidalorsen in patients with hereditary angioedema

Jan 08, 2024

Ionis poised for continued momentum in 2024 with product launches and key advances in robust pipeline of investigational medicines for serious diseases